3-甲氧基环丁胺 | 1234615-98-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-甲氧基环丁胺
• 英文名称: 3-methoxycyclobutan-1-amine
• 英文别名: cis-3-methoxycyclobutylamine；3-Methoxycyclobutanamine
• CAS: 1234615-98-5
• 化学式: C₅H₁₁NO
• mdl: MFCD17015924
• 分子量: 101.148
• InChiKey: CTZHBPUHGUPFSN-UHFFFAOYSA-N

物化性质

• 沸点：
  122.1±33.0 °C(Predicted)
• 密度：
  0.97±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酸 、 3-甲氧基环丁胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 2-fluoro-N-(3-methoxycyclobutyl)-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzamide
  参考文献：
  名称：

  [EN] LOW AFFINITY POLY(AD-RIBOSE) POLYMERASE 1 DEPENDENT CYTOTOXIC AGENTS
  [FR] AGENTS CYTOTOXIQUES DÉPENDANT DE LA POLY(AD-RIBOSE) POLYMÉRASE-1 DE FAIBLE AFFINITÉ

  摘要：

  本公开提供公式（I）或（II）的化合物，药学上可接受的盐、同位素变体、立体异构体或其混合物。还提供了包含该化合物的制药组合物，治疗受体内聚合酶-1介导的疾病或障碍的方法，检测聚合酶-1介导的神经退行性疾病或障碍的方法，或监测受体内癌症治疗的方法。在某些实施例中，聚合酶-1介导的疾病或障碍是神经退行性疾病或癌症。

  公开号：

  WO2019169156A1

文献信息

• [EN] IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS IMIDAZO[4,5C]QUINOLINE-2-ONE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2017076898A1

  公开（公告）日：2017-05-11

  The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R1, R2, R3 and R4 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

  该规范通常涉及式(I)的化合物及其药用盐，其中R1、R2、R3和R4具有本规范中定义的任何含义。该规范还涉及使用式(I)的化合物及其盐来治疗或预防ATM介导的疾病，包括癌症。该规范进一步涉及包含取代咪唑并[4,5-c]喹啉-2-酮化合物及其药用盐的药物组合物；包含这些化合物和盐的试剂盒；制造这些化合物和盐的方法；以及在这种制造中有用的中间体。
• MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS
  申请人：Lynch Rosemary

  公开号：US20130196982A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of formula (I) wherein X 1 , X 2 , R 1 to R 4 , m, n have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

  本发明涉及式（I）的化合物，其中X1、X2、R1至R4、m、n的含义如所述和权利要求书中所述。所述化合物可用于治疗或预防与mTOR相关的疾病和障碍，作为mTOR的抑制剂。本发明还涉及包括所述化合物的制药组合物，以及作为药物的使用和制备这样的化合物。
• Morpholino substituted urea derivatives as mTOR inhibitors
  申请人：Taylor Jessica

  公开号：US09249129B2

  公开（公告）日：2016-02-02

  The invention relates to compounds of formula (I) wherein X1, X2, R1 to R4, m, and n have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of such compounds as well as the use as medicaments.

  本发明涉及公式（I）的化合物，其中X1，X2，R1至R4，m和n的含义如所述描述和权利要求所示。该化合物可用于抑制mTOR以治疗或预防与mTOR相关的疾病和障碍。本发明还涉及包括该化合物的药物组合物、该化合物的制备以及用作药物的用途。
• [EN] 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1<br/>[FR] 2-AMINOQUINAZOLINE 7-PHÉNYL SUBSTITUÉE, INHIBITEURS DE HPK1
  申请人：MERCK SHARP & DOHME

  公开号：WO2022098806A1

  公开（公告）日：2022-05-12

  Compounds of the following formula (I); or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.

  以下公式（I）的化合物或其药学上可接受的盐是血液祖细胞激酶1（HPK1）的抑制剂，可用于治疗与HPK1相关的疾病或紊乱。本文还披露了这些化合物在潜在的治疗或预防HPK1相关疾病或紊乱中的用途。本文还披露了包含一种或多种化合物的组合物。本文还披露了这些组合物在潜在的预防或治疗HPK1相关疾病或紊乱中的用途。
• [EN] OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS OXALAMIDE ET COMPOSITIONS POUR TRAITER DES AFFECTIONS ASSOCIÉES À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2022150549A1

  公开（公告）日：2022-07-14

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及的化合物（例如，化合物或药物可接受的盐，和/或水合物，和/或共晶体，和/或化合物的药物组合）可抑制（例如，对抗）干扰素基因刺激剂（STING）。这些化合物可用于治疗某种病症，疾病或障碍，其中增加（例如，过度）STING激活（例如，STING信号传导）有助于该病理和/或症状和/或病情的进展（例如，癌症）在受体（例如，人类）中。本公开还涉及包含相同物质的组合物以及使用和制备相同物质的方法。